Literature DB >> 7506760

Extracellular cGMP in the hippocampus of freely moving rats as an index of nitric oxide (NO) synthase activity.

F Vallebuona1, M Raiteri.   

Abstract

The nitric oxide (NO) synthase/cGMP pathway has been studied in vivo in the adult rat hippocampus by monitoring the levels of extracellular cGMP during microdialysis in conscious unrestrained animals. The basal cGMP efflux was concentration-dependently reduced upon local infusion of the NO synthase inhibitor NG-nitro-L-arginine (NARG; 10 microM to 1 mM). The NO donors hydroxylamine and S-nitroso-N-penicillamine, perfused through the dialysis probe at 1 mM, increased by about 200% the extracellular levels of cGMP. The glutamate receptor agonist NMDA (125-500 microM) produced concentration-dependent cGMP responses that were abolished by the selective receptor antagonist D-2-amino-5-phosphonovaleric acid or by NARG. Local perfusion of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX; 1 mM) produced a steady eightfold increase of extracellular cGMP levels. The effect of IBMX was highly sensitive to NARG. The inhibition by NARG of the IBMX-induced cGMP response was reversed when the NO synthase substrate L-arginine was administered. It is concluded that cGMP collected during in vivo microdialysis reflects NO synthase activity in the rat hippocampus. The technique may be utilized to investigate the pathophysiology and the pharmacology of the NO/cGMP pathway in the hippocampus of living animals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506760      PMCID: PMC6576862     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  9 in total

1.  Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo.

Authors:  G Wegener; V Volke; R Rosenberg
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway.

Authors:  E Fedele; Y Jin; G Varnier; M Raiteri
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

3.  Desensitization of AMPA receptors and AMPA-NMDA receptor interaction: an in vivo cyclic GMP microdialysis study in rat cerebellum.

Authors:  E Fedele; M Raiteri
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  In vivo NO/cGMP signalling in the hippocampus.

Authors:  E Fedele; M Marchi; M Raiteri
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

5.  Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptors.

Authors:  G Maura; M Marcoli; O Pepicelli; C Rosu; C Viola; M Raiteri
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

6.  Nitric oxide production in rat thalamus changes with behavioral state, local depolarization, and brainstem stimulation.

Authors:  J A Williams; S R Vincent; P B Reiner
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

7.  Aged neuronal nitric oxide knockout mice show preserved olfactory learning in both social recognition and odor-conditioning tasks.

Authors:  Bronwen M James; Qin Li; Lizhu Luo; Keith M Kendrick
Journal:  Front Cell Neurosci       Date:  2015-03-27       Impact factor: 5.505

8.  Sensitivity to Sevoflurane anesthesia is decreased in mice with a congenital deletion of Guanylyl Cyclase-1 alpha.

Authors:  Yasuko Nagasaka; Martin Wepler; Robrecht Thoonen; Patrick Y Sips; Kaitlin Allen; Jan A Graw; Vincent Yao; Sara M Burns; Stefan Muenster; Peter Brouckaert; Keith Miller; Ken Solt; Emmanuel S Buys; Fumito Ichinose; Warren M Zapol
Journal:  BMC Anesthesiol       Date:  2017-06-14       Impact factor: 2.217

Review 9.  Nitric Oxide Synthase Inhibitors as Antidepressants.

Authors:  Gregers Wegener; Vallo Volke
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.